ArticleThe American journal of pathology2010
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 2 syntheses or guidelines pooled it, 317 citations in OpenAlex.
- MRI features of Stewart-Treves syndrome: a case series and systematic review.Japanese journal of radiology · 2025Pooled it
- Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.Frontiers in oncology · 2025Pooled it
- Effects of prior irradiation on the microenvironment of a radiation-associated breast cancer model increase sensitivity to immune checkpoint inhibition.International journal of radiation oncology, biology, physics · 2026Article
- Primary Bone Vascular Neoplasms: An Integrated Biological Perspective from Bone Pathology to Precision Oncology.Cancers · 2026Review
- Primary multifocal gastrointestinal epithelioid angiosarcoma with MYC amplification: a diagnostic pitfall mimicking poorly differentiated carcinoma: a case report.BMC gastroenterology · 2026Article
- Cutaneous soft tissue tumors in the 5th edition of the World Health Organization classification of skin tumors: key updates and new entities.Journal of pathology and translational medicine · 2026Article
- The Diagnostic Trap in Radiation-Induced Mesothelioma: Kinetic-Morphological Decoupling Masks Molecular Aggression.Cancers · 2026Article
- Novel Therapeutic Approaches for Cutaneous Angiosarcoma, Particularly Focusing on Immune Checkpoint Inhibitors.Cancers · 2025Review
- Article
- TRPS1 expression in breast angiosarcoma.Virchows Archiv : an international journal of pathology · 2025Article
- Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease.Journal of personalized medicine · 2024Review
- Clinical Characteristics, Patterns of Care, and Treatment Outcomes of Radiation-Associated Sarcomas.Cancers · 2024Article
- MicroRNAs and angiosarcoma: are there promising reports?Frontiers in oncology · 2024Review
- Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies.Cancer immunology, immunotherapy : CII · 2023Review
- Current understanding of angiosarcoma: disease biology and evolving treatment.Archives of craniofacial surgery · 2023Article
- Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.The Journal of pathology · 2023Article
- Loss of TSC1 in secondary angiosarcoma of the breast.Clinical case reports · 2023Article
- Patient with composite haemangioendothelioma containing angiosarcoma-like areas in the setting of congenital lymphoedema mimicking Stewart-Treves syndrome: a case report.Diagnostic pathology · 2023Article
- Angiosarcoma of the Breast: Overview of Current Data and Multimodal Imaging Findings.Journal of imaging · 2023Review
- Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study.Therapeutic advances in medical oncology · 2023Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcomas (AS) are rare vascular malignancies that arise either de novo as primary tumors or secondary to irradiation or chronic lymphedema. The cytogenetics of angiosarcomas are poorly characterized. We applied array-comparative genomic hybridization as a screening method to identify recurrent alterations in 22 cases. Recurrent genetic alterations were identified only in secondary but not in primary AS. The most frequent recurrent alterations were high level amplifications on chromosome 8q24.21 (50%), followed by 10p12.33 (33%) and 5q35.3 (11%). Fluorescence in situ hybridization analysis in 28 primary and 33 secondary angiosarcomas (31 tumors secondary to irradiation, 2 tumors secondary to chronic lymphedema) confirmed high level amplification of MYC on chromosome 8q24.21 as a recurrent genetic alteration found exclusively in 55% of AS secondary to irradiation or chronic lymphedema, but not in primary AS. Amplification of MYC did not predispose to high grade morphology or increased cell turnover. In conclusion, despite their identical morphology, secondary AS are genetically different from primary AS and are characterized by a high frequency of high level amplifications of MYC. This finding may have implications both for the diagnosis and treatment of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.